Fenofibrate NDC 42385-936

NDC codes

FDA NDC Directory

Product NDC (as listed)42385-936Labeler and product segments. Claims need a package NDC.

Product NDC at billing width42385-0936Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
42385-936-05	42385093605	500 TABLET, FILM COATED in 1 BOTTLE (42385-936-05)Marketed from Jan 13, 2020
42385-936-11	42385093611	1000 TABLET, FILM COATED in 1 BOTTLE (42385-936-11)Marketed from Jan 13, 2020
42385-936-30	42385093630	30 TABLET, FILM COATED in 1 BOTTLE (42385-936-30)Marketed from Jan 13, 2020
42385-936-90	42385093690	90 TABLET, FILM COATED in 1 BOTTLE (42385-936-90)Marketed from Jan 13, 2020

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Fenofibrate
Generic name (nonproprietary): fenofibrate
Active ingredients: Fenofibrate — 160 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Laurus Labs Limited
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 210606
Marketing start: Jan 13, 2020
Listing expires: Dec 31, 2026
Identifiers: Product ID 42385-936_f0dfffd1-9c2c-0cbd-e053-2a95a90a908cSPL ID f0dfffd1-9c2c-0cbd-e053-2a95a90a908cSPL set ID 8e58c13a-8088-4fed-86cc-52530de5aa45RxCUI 349287, 351133UNII U202363UOSUPC 0342385936902, 0342385935905
Pharmacologic class: Peroxisome Proliferator Receptor alpha Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N442385093605 followed by a unit qualifier and the quantity

Package 42385-0936-05. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 28, 2022.

Indications (excerpt from the label)

Fenofibrate is a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet: To reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.1 ). For treatment of adult patients with severe hypertriglyceridemia ( 1.2 ). Limitations of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus ( 5.1 ). 1.1 Primary Hypercholesterolemia or Mixed Dyslipidemia Fenofibrate tablets are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (To…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 210606

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 210606
Product	Strength	Form · route	Labeler	Product NDC
Fenofibrate	Fenofibrate 54 mg/1	Tablet, Film coatedOral	Leading Pharma, LLC	69315-289
Fenofibrate	Fenofibrate 160 mg/1	Tablet, Film coatedOral	Leading Pharma, LLC	69315-290
Fenofibrate	Fenofibrate 54 mg/1	Tablet, Film coatedOral	Laurus Labs Limited	42385-935